Determining a viral load threshold for pre-emptive therapy for cytomegalovirus infection in transplant patients using real time PCR monitoring

ISRCTN ISRCTN03307563
DOI https://doi.org/10.1186/ISRCTN03307563
ClinicalTrials.gov number NCT00947141
Secondary identifying numbers N0256119271
Submission date
12/09/2003
Registration date
12/09/2003
Last edited
14/02/2020
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Paul D Griffiths
Scientific

Department of Virology
The Royal Free & University Medical School
Pond Street
Hampstead
London
NW3 2QG
United Kingdom

Phone +44 (0)20 7830 2997 ext 4951
Email p.griffiths@medsch.ucl.ac.uk

Study information

Study designOpen-label randomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleDetermining a viral load threshold for pre-emptive therapy for cytomegalovirus infection in transplant patients using real time PCR monitoring
Study objectivesThe aim of this study is to determine if quantitative measures of CMV viraemia can be applied to improve the treatment of CMV infection, and to evaluate the threshold of CMV viral load for initiation or discontinuation of pre-emptive therapy.
Ethics approval(s)Research Ethics Committee (REC), 20/11/2002, ref: 6077, re-approved on the 16th November following an MHRA audit
Health condition(s) or problem(s) studiedCytomegalovirus (CMV) infection
InterventionGroup A: 72 patients with low level CMV reactivation
Group B: 106 patients receiving pre-emptive therapy
Intervention typeOther
Primary outcome measureCurrent information as of 29/07/2009:
1. The number of patients in Group A with a low level of CMV reactivation who subsequently develop a viral load greater than 3000 copies/ml.
2, The number of patients in Group B who develop a second episode of a viral load above 3000 copies/ml after therapy has been discontinued at the defined viral load cut-offs.

Initial information at time of registration:
Number of patients receiving another course of therapy because viral load increases above 3000 copies/ml.
Secondary outcome measuresCurrent information as of 29/07/2009:
1. The duration of antiviral therapy needed to treat CMV viraemia
2. The rate of increase in viral load prior to starting pre-emptive therapy
3. Correlation of viral loads with CMV-specific immune function
Overall study start date05/12/2002
Completion date01/04/2011

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants178
Key inclusion criteria178 patients in total: stem cell, renal and liver transplant recipients with CMV reactivation
Key exclusion criteriaDoes not meet inclusion criteria
Date of first enrolment05/12/2002
Date of final enrolment01/04/2011

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

The Royal Free & University Medical School
London
NW3 2QG
United Kingdom

Sponsor information

The Royal Free & University College Medical School - Research and Development (UK)
Hospital/treatment centre

Medical School Admin Offices
Room G649
Rowland Hill Street
London
NW3 2PF
England
United Kingdom

ROR logo "ROR" https://ror.org/01ge67z96

Funders

Funder type

Hospital/treatment centre

The Royal Free Hampstead NHS Trust (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 29/09/2016 Yes No

Editorial Notes

14/02/2020: ClinicalTrials.gov number added.
18/04/2017: Publication reference added.
29/07/2009: This record was extensively updated. All updates can be found under the relevant field with the above update date. Please also note that the public title 'Optimising the treatment of cytomegalovirus infection' has been updated. The sponsor information has been changed - the initial sponsor was the Department of Health (UK). The trial has also been extended - the initial anticipated end date was 31/12/2003.